Scarica l'app Stockscreener
82.34
2.00%
-1.68
Precedente Chiudi:
$84.02
Aprire:
$84.64
Volume 24 ore:
583.20K
Relative Volume:
0.60
Capitalizzazione di mercato:
$6.59B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-26.56
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
+3.46%
1M Prestazione:
+11.08%
6M Prestazione:
+102.16%
1 anno Prestazione:
+124.79%
Intervallo 1D:
$82.05
$86.18
Intervallo di 1 settimana:
$76.52
$86.18
Portata 52W:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
82.34 | 6.72B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
What is the long term forecast for Kymera Therapeutics Inc. stock2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Kymera Therapeutics Touts Once-Daily Oral “Biologics-Like” KT-621 at Guggenheim Conference - Yahoo Finance
Kymera Therapeutics discloses new STAT6 inhibitors - BioWorld MedTech
Will Kymera Therapeutics Inc. face regulatory challenges2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
What is Kymera Therapeutics Inc. s 5 year growth outlookMarket Sentiment Summary & Weekly Top Gainers Alerts - mfd.ru
Kymera at Guggenheim Biotech Summit: Exploring Oral Drug Potential By Investing.com - Investing.com Canada
Is Kymera Therapeutics Inc. a strong candidate for buy and holdProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Candriam S.C.A. - MarketBeat
How Kymera Therapeutics Inc. stock performs in weak economyIndex Update & Fast Entry and Exit Trade Plans - mfd.ru
KT-621 Phase 2b Expansion Across Type 2 Diseases Could Be A Game Changer For Kymera Therapeutics (KYMR) - Sahm
Aug Update: What makes Kymera Therapeutics Inc. stock attractive to growth fundsDividend Hike & Free Safe Capital Growth Stock Tips - mfd.ru
Certain Warrants of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Common Stock of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
CEO Moves: Will FATN outperform small cap indexesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - baoquankhu1.vn
Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621 - Sahm
Smart Money: What are Kymera Therapeutics Incs earnings expectationsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
KYMR initiates dosing in mid-stage asthma study of lead candidate - MSN
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Investing News Network
Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus - DirectorsTalk Interviews
(KYMR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate - Yahoo Finance
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader By Investing.com - Investing.com South Africa
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader - Investing.com India
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader - TradingView
Analyst Barclays Raises Price Target for Kymera Therapeutics (KY - GuruFocus
Aug Movers: Can Kymera Therapeutics Inc benefit from deglobalization2025 Fundamental Recap & Weekly Breakout Watchlists - baoquankhu1.vn
Kymera Therapeutics (KYMR) Stock Analysis: Exploring A 64% Upside Potential - DirectorsTalk Interviews
What is the earnings history of Kymera Therapeutics Inc.2025 Trading Recap & Reliable Price Breakout Signals - mfd.ru
Responsive Playbooks and the KYMR Inflection - Stock Traders Daily
Aug Volume: What is the long term forecast for Kymera Therapeutics Inc stockWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm
Is BRID stock overvalued or fairly pricedJuly 2025 Sentiment & Community Trade Idea Sharing Platform - baoquankhu1.vn
Kymera Therapeutics director Esposito sells $373k in shares By Investing.com - Investing.com Nigeria
Kymera Therapeutics director Esposito sells $373k in shares - Investing.com
This drugmaker's stock is soaring over 40% Monday - MSN
Signal Recap: Does Loop Industries Inc outperform in volatile marketsMarket Activity Report & Safe Swing Trade Setups - baoquankhu1.vn
Exit Recap: Can Kymera Therapeutics Inc benefit from deglobalizationJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Portfolio Update: What is Kymera Therapeutics Incs 5 year growth outlookWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage? - Sahm
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):